Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD5 | P21918 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2281976 | 0.81 | C1S (0.39) | KDM1AMEN1KMT2AALDH1A1 | |
| SCHEMBL194639 | 0.77 | KDM1A (0.50) | KDM1AMEN1KMT2AHTR2AHTR2C | |
| SCHEMBL12641997 | 0.75 | KDM1A (0.44) | KDM1AMEN1KMT2AHTR2AHTR2C | |
| SCHEMBL744929 | 0.75 | KDM1A (0.41) | KDM1AMEN1KMT2AHTR2AHTR2C | |
| SCHEMBL723465 | 0.74 | ACHE (0.46) | MEN1KMT2AHTR2AHTR2CHTR2B | |
| SCHEMBL7833417 | 0.74 | CYP3A4 (0.46) | MEN1KMT2AALDH1A1MAPK1TSHR | |
| SCHEMBL921104 | 0.74 | ALDH1A1 (0.46) | MEN1KMT2AHTR2AHTR2CHTR2B | |
| SCHEMBL3124390 | 0.74 | TAAR1 (0.42) | KDM1AHTR2AHTR2CHTR2BRCOR1 | |
| SCHEMBL2469369 | 0.74 | TAAR1 (0.42) | KDM1AMEN1KMT2AHTR2AHTR2C | |
| SCHEMBL3117055 | 0.74 | IDO1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142493-B1 | ISO CA-4 AND ANALOGUES THEREOF AS POTENT CYTOTOXIC AGENTS INHIBITING TUBULINE POLYMERISATION | CENTRE NAT RECH SCIENT (FR) | 2019-03-27 | — | — | EP | disclosed |
| US-10155763-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | TIUMBIO CO., LTD. (KR) | 2018-12-18 | — | — | US | disclosed |
| EP-2731949-B1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | TIUMBIO CO LTD (KR) | 2018-04-04 | — | — | EP | disclosed |
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2419419-B1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-03 | — | — | EP | disclosed |
| US-20140242606-A1 | PROBE FOR iFRET AND USE THEREOF | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-28 | — | — | US | disclosed |
| EP-2731949-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | SK Chemicals Co., Ltd. (KR) | 2014-05-21 | — | — | EP | disclosed |
| US-8604042-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8513229-B2 | 4-Azetidinyl-1-phenyl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-20 | — | — | US | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2002024649-A1 | SUBSTITUTED AMINO-AZA-CYCLOALKANES USEFUL AGAINST MALARIA | ACTELION PHARMACEUTICALS LTD (CH) | 2002-03-28 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6118001-A | ANTICANCER AGENT; ANTIARTHRITIC AGENT | DARWIN DISCOVERY, LTD. (GB) | 2000-09-12 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0968182-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998005635-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
| EP-0537517-B1 | Method for the preparation of 2,2-difluorobenzo(1,3)dioxolecarbaldehydes and intermediates | BAYER AG (DE) | 1997-01-22 | — | — | EP | disclosed |
| EP-0537517-A1 | Method for the preparation of 2,2-difluorobenzo(1,3)dioxolecarbaldehydes and intermediates | BAYER AG (DE) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155763-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | ACVR1, ACVRL1, ALK | KDM1A 1043/4885MEN1 2817/4885KMT2A 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.